Drug intelligence / Profile preview

H018 ointment

Development stage: Unknown
Lead developer: Institute of Dermatology, Chinese Academy of Medical Sciences
Modality: Small Molecules
Administration: Topical

Overview

H018 ointment is an investigational topical small molecule Janus kinase (JAK) inhibitor being developed by the Institute of Dermatology, Chinese Academy of Medical Sciences. It is primarily targeted for the treatment of vitiligo, an autoimmune skin condition characterized by the loss of pigment-producing melanocytes. By inhibiting the JAK signaling pathway, H018 aims to suppress the immune-mediated destruction of melanocytes and promote repigmentation. The drug is currently in Phase I clinical development, with studies evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers.

Targets

JAK (Janus kinase family)

Beyond the preview

Go deeper on H018 ointment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H018 ointment.

Explore the full profile